Biodesix (BDSX) Other Operating Expenses (2019 - 2026)

Biodesix (BDSX) has 8 years of Other Operating Expenses data on file, last reported at -$25.1 million in Q1 2026.

• Quarterly Other Operating Expenses fell 20.77% year-over-year to -$25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (up 180.67% YoY) and the FY2025 annual result came in at $21.3 million, up 34.49% from the prior year.
• Other Operating Expenses retreated to -$25.1 million in Q1 2026, from $90.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $90.2 million in Q4 2025 to a low of -$75.9 million in Q4 2023.
• A 5-year average of -$5.0 million and a median of $3.2 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2023 — Other Operating Expenses sank 2394.89% — and 2025, when it surged 2587.49%.
• Tracing BDSX's Other Operating Expenses over 5 years: stood at $3.3 million in 2022, then slumped by 2394.89% to -$75.9 million in 2023, then surged by 104.42% to $3.4 million in 2024, then surged by 2587.49% to $90.2 million in 2025, then slumped by 127.78% to -$25.1 million in 2026.
• The last three Other Operating Expenses figures came in at -$25.1 million (Q1 2026), $90.2 million (Q4 2025), and -$22.2 million (Q3 2025), per Business Quant data.